Hepyx is an early-stage clinical drug development platform.
To improve the quality of life and prognosis of patients with advanced liver disease, through the repurposing of existing drugs and the development of novel therapies.
To advance a pipeline of therapies through clinical trials and progress to commercialisation.
To meet the global challenge of liver disease in an effective and scalable way, through collaboration and transparency. The area of advanced liver disease is vast, with a great unmet clinical need - over 100 million people globally have cirrhosis of the liver, due to obesity, viral infection, or alcohol.